GSK256066 significantly inhibited release of both IL-2 (mean percent inhibition 40.1 % in S, 47.9 % in COPD) and IFNγ (mean percent inhibition 28.5 % in S, 45.8 % in COPD) from pulmonary CD8 cells with no significant differences between patient groups (Fig. 3). Here, CD8A is linked to chronic obstructive pulmonary disease.